Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on May 20, 2006

One thing that is not yet definite however, is how broadly the vaccine will be used. Merck said the vaccine could be used in females age 9 to 26, but would work best when given to girls before they begin having sex. Merck also suggested using it in young boys, who cannot get cervical cancer, but play a role in controlling its prevalence.
On the business scene:
Some investors have been bidding up shares of MedImmune (nasdaq: MEDI - news - people ), the Gaithersburg, Md.-based maker of a drug for treating infections in premature infants, because the biotech has licensing agreements for key technology in the HPV vaccines of both Merck and GlaxoSmithKline, which is close behind with a similar preventative. Australia's CSL Limited, which is not traded in the U.S., may also receive a royalty.
Bernstein's Porges estimates that MedImmune could get $175 million in 2010 royalties from both vaccines, adding 46 cents to its earnings per share; that could be worth $7 to MedImmune shares, he says. Porges estimates 2010 worldwide sales of $3.3 billion for Gardasil, compared to $940 million for Glaxo's Cervarix.
Read more from Forbes, On Guard for Gardasil, and from Merck's press release.
[Photo: Institute of Human Virology]
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/22376
Mr Wong
Vote for FDA Advisory Panel Approves Gardasil Vaccine Against Cervical Cancer:
|
Rating: 9.66 out of 44 vote(s) cast.
|
Response from:
Trusted.MD Network
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







